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Abstract 
Objective: Substance use is common in first-episode psychosis, and complicates the 
accurate diagnosis and treatment of the disorder. The differentiation of substance-
induced psychotic disorders (SIPD) from primary psychotic disorders (PPD) is 
particularly challenging. This cross-sectional study compares the clinical, substance 
use and functional characteristics of substance using first episode psychosis patients 
diagnosed with a SIPD and PPD.  
Method: Participants were 61 young people (15-24 years) admitted to a psychiatric 
inpatient service with first episode psychosis, reporting substance use in the past 
month. Diagnosis was determined using the Psychiatric Research Interview for DSM-
IV Substance and Mental disorders (PRISM-IV). Measures of clinical (severity of 
psychotic symptoms, level of insight, history of trauma), substance use 
(frequency/quantity, severity) and social and occupational functioning were also 
administered.  
Results: The PRISM-IV differentially diagnosed 56% of first episode patients with a 
SIPD and 44% with a PPD. Those with a SIPD had higher rates of substance use and 
disorders, higher levels of insight, were more likely to have a forensic and trauma 
history and had more severe hostility and anxious symptoms than those with a PPD. 
Logistic regression analysis indicated a family history of psychosis, trauma history 
and current cannabis dependence were the strongest predictors of a SIPD. Almost 
80% of diagnostic predictions of a SIPD were accurate using this model. 
 
Conclusions: This clinical profile of SIPD could help to facilitate the accurate 
diagnosis and treatment of SIPD versus PPD in young people with first episode 
psychosis admitted to an inpatient psychiatric service.  
Keywords: Psychosis, Substance use, Substance-induced, First-episode, Youth, 
Comorbidity. 
  
 1.0 Introduction 
Substance use and misuse is common among individuals with first-episode psychosis, 
with between 40 and 70% meeting criteria for a co-occurring substance use disorder, 
excluding tobacco dependence (Lambert et al., 2005). Despite this, surprisingly little 
research has sought to differentiate substance-induced psychotic disorders (SIPD) 
from primary psychotic disorders (PPD) with concurrent substance use, or determine 
if these disorders have a differential course and outcomes. This is problematic, as 
misdiagnosis with a PPD may result in stigmatization, and the unnecessary use of 
long-term medication, while those diagnosed with a SIPD tend to be excluded from 
appropriate treatment programs (American Psychiatric Association, [APA] 2000; 
Richie et al., 1994; Schanzer et al., 2006). 
 
Diagnostic and Statistical Manual IV-Text Revision (DSM-IV-TR) criteria for SIPD 
are difficult to apply in practice due to the similarity of the psychogenic effects of 
certain substances (e.g. cannabis and amphetamines) with symptoms of psychosis, as 
well as the lack of sufficient periods of abstinence (4 weeks) to determine if 
symptoms are substance-induced (Hasin et al., 2006; Rounsaville, 2007; Schuckit, 
2006). DSM-IV-TR criteria provide little guidance on the frequency, severity and 
duration of psychotic symptoms or substance use required for a SIPD (Mathias et al., 
2008). While structured clinical interviews such as the Psychiatric Research Interview 
for DSM-IV Substance and Mental disorders (PRISM-IV) facilitate reliable 
differentiation of SIPD from PPD, the length and intensive training required precludes 
its routine use (Caton et al., 2000; Hasin et al., 2006; Mathias et al., 2008).  
 
There is increasing interest in the use of the PRISM and other diagnostic interviews to 
differentiate substance-induced from primary psychiatric disorders among substance 
users recruited from community and treatment seeking samples (Dakwar et al., 2011; 
Schuckit et al., 2007; Torrens et al., 2011; Torrens et al., 2004). The majority of this 
research has focused on substance-induced depression, and only two cohort studies 
examining the differential characteristics and outcomes of psychotic patients 
diagnosed with SIPD and PPD have been conducted to date (Arendt et al., 2005; 
Caton et al., 2005). Using the PRISM-IV, Caton et al., (2005) found 44% (N=169) of 
adults in the early phases of psychosis had a SIPD and 56% (N=217) had a PPD with 
concurrent substance use. Individuals with SIPD were more likely to report parental 
substance use, have concurrent drug dependence and visual hallucinations, and a less 
severe symptom profile compared to those diagnosed with a PPD.  A 12 month follow 
up of this cohort found patients with SIPD were more likely to achieve psychotic 
symptom remission (Caton et al., 2006). At two years follow up, both groups had 
improved over time on substance dependence, psychotic symptoms and psychosocial 
outcomes, despite receiving minimal mental health or substance abuse treatment 
(Drake et al., 2011). However, the PPD group had consistently more severe positive 
and negative symptoms and the SIPD group had higher rates of alcohol or drug 
dependence over time. The only other study reporting the differential outcomes of 
psychotic patients with a SIPD and PPD used data based on clinical diagnoses 
extracted from a central psychiatric register (Arendt et al., 2005).  
 
Thus, while there is evidence that individuals in the early-phase of psychosis 
diagnosed with a SIPD and PPD have distinct characteristics, course and outcomes, 
research is yet to examine the rates and differential characteristics of SIPD and PPD 
among young first episode psychosis patients during an acute psychiatric admission. 
The differential diagnosis of SIPD and PPD is particularly challenging during an 
acute admission when psychotic symptoms are the most severe, and the identification 
of possible markers of these disorders could simplify their recognition and treatment. 
Young first episode patients are an important group to study due to the high rates and 
adverse consequences of substance use, misuse or disorder in this population, and the 
potential prognostic impact of the accurate diagnosis and treatment of psychosis and 
substance use. 
 
This study examined the differential characteristics of young first episode patients 
with a SIPD and PPD during an acute admission to a psychiatric inpatient unit. Based 
on a similar study in adults, we hypothesized that there would be differences in the 
demographic, clinical, substance use and functional characteristics of young people 
with a SIPD and PPD (Caton et al., 2005). No specific research hypotheses were 
proposed, as this was the first study to examine this research question in young  
 
2.0 Method 
2.1 Participants  
Participants were 61 young people with first episode psychosis and concurrent 
substance use (≥ 6 occasions in the past 12 months, with most recent use occurring in 
the last 30 days), admitted to the inpatient unit of the Early Psychosis Prevention and 
Intervention Centre (EPPIC), a specialist FEP early intervention program for young 
people (aged 15-24 years) in Melbourne, Australia. Individuals were excluded if their 
first episode of psychosis commenced over 12 months prior to study enrolment, had 
an estimated IQ < 70, or were from a non-English speaking background.  
2.2 Measures 
2.2.1 Diagnostic assessment 
Sections 2, 3 and 8 of the PRISM-IV were administered to provide lifetime and 
current DSM-IV diagnoses of SIPD, PPD and substance use disorders (Hasin et al., 
1996). PRISM interviewer instructions and probes assist in determining the 
etiological timelines for the onset (age) of first and recent (how many months/weeks 
or days ago) substance use and psychiatric symptoms. To assist with this process, 12 
month and lifetime patterns (chronic intoxication/binge use; abstinence/minimal use) 
of substance use are initially completed, prior to questions about psychiatric 
symptoms. The PRISM has high levels of test-retest reliability for the differential 
diagnosis of SIPD and PPD (kappa = .70 - .83) (Torrens et al., 2004). To reduce time, 
the major depressive and manic episode modules of the Mini International 
Neuropsychiatry Interview (MINI; Lecrubier et al., 1997) were administered, rather 
than the equivalent PRISM modules.  
 
2.2.2 Clinical and functional measures 
The 24-item Brief Psychiatric Rating Scale (BPRS; Lukoff et al., 1986) measured the 
severity of positive, negative and general psychopathology symptoms in the last 
month. This measure has well established reliability and validity in first episode 
psychosis (Ventura et al., 2000). Information on the patient’s personal and family 
history of psychotic and SUDs and duration of untreated psychosis (time period 
between the first signs of psychotic symptoms and first contact with psychiatric 
services) was also collected. .  
 
The Composite International Diagnostic Interview -Trauma List (CIDI-TL; World 
Health Organisation, 1997) was used to generate a list of life events meeting DSM-IV 
criteria A1 and A2 for exposure to a traumatic event. Multiple experiences of a single 
category of trauma (e.g. rape) were counted as one exposure. The Scale to Assess 
Unawareness of Mental Disorders (SUMD; Amador et al., 1993) was used to measure 
level of insight, where lower scores indicate greater insight.  
 
The Global Assessment of Functioning (GAF; APA, 2000) and DSM-IV Social and 
Occupational Functioning Assessment Scale (SOFAS; APA, 2000) were also 
administered. The Pre-morbid Adjustment Scale (PAS; Cannon-Spoor, 1982) 
provided a measure of the participants’ level of pre-morbid adjustment in the 6 
months prior to first psychiatric hospitalization.  
 
2.2.3 Substance use 
The frequency and quantity of ten classes of substance use (tobacco, alcohol, 
cannabis, amphetamines, ecstasy, cocaine, hallucinogens, inhalants, heroin and 
valium) in the past month was collected using the time line follow back (TLFB) (Fals 
Stewart et al., 2000). Information on the age of onset (lifetime and regular) of alcohol 
and cannabis use was collected from the PRISM.   
 
2.3 Procedure 
Ethics approval to conduct the trial was obtained from the Melbourne Health    
Human Research and Ethics Research Committee. The assessment measures were 
administered by the first author (a third year Doctor of Psychology [Clinical] student), 
in a private interview room, once written informed consent was obtained. Only 
patients who were considered clinically stable enough to provide voluntary informed 
consent by their treating nurse or doctor were approached. PRISM-IV training was 
provided by the second author, a clinical psychologist and certified PRISM trainer. If 
the PRISM diagnosis was unclear after the 1 – 2 hour interview, a diagnostic 
consensus process was used. Participants were reimbursed $20 AUD for their time 
and travel-related expenses.   
 
2.4 Data Analysis          
Following examination of the data, the duration of untreated psychosis variable was 
transformed (log 10) due to positive skewness (Tabachnick and Fidell, 2007  ). 
Between-group comparisons across demographic, clinical, substance use and 
functional variables were made using chi-square and independent t-tests (Statistical 
Package for Social Sciences [SPSS v16]).   
 
The three historical and clinical variables identified as most significantly related 
(Spearman ρ [> 0.25] and Chi-square tests) to SIPD diagnosis were entered into 
separate logistic regression analyses. A final logistic regression was then performed, 
entering the three strongest predictors of a SIPD into the analysis.  
 
3.0 Results  
3.1 Sample 
3.1.1 Recruitment 
Over 16 months, 296 individuals with first episode psychosis presented to EPPIC. Of 
these, 61% (n=180) reported comorbid substance use in the previous month. Seventy 
individuals were approached by the first author (one day a week over the 16 month 
period) and 61 (87%) consented to participate. Individuals refused due to suspicion 
(n=6; 67%), disinterest (n=2; 22%), or were too acutely unwell (n=1; 11%). The 
average time from admission to interview was 7.5 days (SD=5.3).  
 
Insert Table 1 about here 
 
3.1.2 Sample characteristics  
The sample had a mean age of 21 years, and were predominantly male, unemployed 
with low levels of education (see Table 1). The sample had high rates of substance 
dependence and severe levels of psychopathology (see Tables 2 and 3). The PRISM 
indicated 27 (44.3%) of first episode patients had a SIPD, while the remaining 34 
(55.7%) had a PPD with concurrent substance use. The mean amount of antipsychotic 
medication equated to 4.5mg haloperidol per day (including regular and pro re nata 
[PRN] medication). Antidepressants and mood stabilizers were prescribed to 14.8% 
(n=9) and 9.8% (n= 6) of patients respectively. Anxiolytics, predominantly 
benzodiazepines, were widely used as a PRN medication (n=53, 86.9%). Information 
on the other demographic, historical, substance use and clinical characteristics of the 
total sample, SIPD and PPD groups are provided in Tables 1 to 3.  
 
Insert Table 2 about here 
 
3.2 Group comparison: SIPD and PPD  
There were no significant group differences on demographic variables (see Table 1). 
Inpatients with a SIPD were significantly more likely to have a forensic history and a 
current diagnosis of cannabis, stimulant or polysubstance dependence (see Table 2). 
They also reported significantly higher levels of cannabis and methamphetamine use 
in the past month. The PPD group reported a significantly higher number of days 
abstinent in the past month. There were no differences in the age of onset of first or 
regular alcohol or cannabis use.  
 
Insert Table 3 about here 
 
Overall the sample had severe levels of psychopathology (see BPRS; Table 3). The 
SIPD group reported higher levels of hostility and anxiety, and were more likely to 
have experienced a traumatic event (on the CIDI-TL). However, the PPD group 
reported their first traumatic event occurred at a significantly younger age. There were 
no significant group differences in the amount of medications prescribed, types of 
traumatic events experienced, level of pre-morbid adjustment (PAS), global (GAF), 
social or occupational functioning (SOFAS).  
 
The SIPD group were significantly more aware about the social consequences of a 
mental disorder, that they were experiencing a mental illness and/or hallucinations, 
and were in need of treatment (see Table 3). The PPD group were significantly more 
likely to attribute delusional symptoms to a mental illness or substance abuse.  
 
 
3.3 Prediction of a SIPD  
3.3.1 Historical variables 
Family history of psychosis (χ2= [1, N=61] = 5.48, p=.02), forensic history (χ2= [1, 
N=61] = 5.24, p=.02) and any history of trauma (χ2= [1, N=61] = 8.52, p=.004) were 
the historical variables most strongly related to a diagnosis of SIPD. Those with SIPD 
were less likely to have a family history of psychosis, and more likely to have 
forensic and trauma histories. A family history of psychosis and trauma history 
emerged as significant predictors for SIPD in the logistic regression analysis, 
accounting for 33.7% (Nagelkerke R squared) of the variance in diagnostic status (see 
Table 4).  
 
3.3.2 Clinical Variables 
The hostility item of the BPRS (N = 61, ρ = .29, p =.02), current cannabis dependence 
(χ2= [1, N=61] = 13.46, p<.001) and insight into the mental disorder (N = 61, ρ = -
0.30, p = .02) were the clinical variables most strongly related with SIPD. Current 
cannabis dependence was the only significant predictor of a SIPD in the logistic 
regression analysis, accounting for 40.8% (Nagelkerke R squared) of the variance in 
diagnostic status. 
 
Insert Table 4 about here 
 
3.3.3 Combined model 
A family history of psychosis, history of trauma and current cannabis dependence 
were entered into the analysis. All variables predicted the presence of a SIPD and 
accounted for 50.3% (Nagelkerke R squared) of the variance in diagnostic status. 
Individuals with a family history of psychosis were 0.18 less likely to have a SIPD 
than a PPD. Participants with a trauma history were 23 times more likely to have a 
SIPD and those with current cannabis dependence were 15 times more likely to have 
a SIPD. Overall 78.7% of diagnostic predictions were accurate using this model. 
 
4.0 Discussion  
This study is the first to distinguish the characteristics of young first episode 
psychosis patients with a SIPD from those with PPD during an acute psychiatric 
admission. A high rate of SIPD (56%) was found on the PRISM-IV in this sample of 
61 FEP patients with concurrent substance use. Individuals with a SIPD were less 
likely to have a family history of psychosis, had higher levels of insight and more 
severe hostility and anxiety than those with a PPD. The SIPD group also reported 
significantly higher levels of recent cannabis and stimulant use, higher rates of 
cannabis, stimulant and polysubstance dependence, and were more likely to have a 
forensic history. Logistic regression analysis indicated patients with a family history 
of psychosis were 0.18 times less likely to have a SIPD, while those with a trauma 
history or current cannabis dependence were 23 and 15 times more likely to have a 
SIPD, respectively.  
 
A higher rate of SIPD (56%) was found among first episode patients admitted to an 
inpatient unit than previously reported by Caton (44%; 2005) among early phase 
psychosis patients recruited from emergency departments. Individuals with SIPD in 
both studies had higher rates of substance use disorders and higher levels of insight. 
However, inconsistent results were found on demographic and symptom variables. 
These differential findings may reflect the younger mean age of participants in the 
current study, and the different recruitment criteria, sites and measures of 
psychopathology used. In addition, patients in the current study were current 
inpatients with severe levels of psychopathology on the BPRS, whereas those in the 
Caton study were only required to have at least one psychotic symptom to participate 
and had mild levels of psychopathology on the Positive and Negative Symptom Scale 
(PANSS) at baseline. Further research among first episode patients with differing 
levels of psychopathology, recruited from a variety of treatment settings is required to 
further elucidate the characteristics of first episode patients with a SIPD and PPD.  
 
SIPD but not PPD was associated with the presence of a forensic history in the current 
study. Caton et al. (2005) found higher rates of antisocial personality disorder (ASPD) 
among individuals with SIPD, but did not find any difference in the imprisonment 
rates of FEP patients with SIPD versus PPD. While psychotic disorders have been 
strongly associated with increased rates of aggression and ASPD, further research is 
required to determine if there are differential rates of ASPD, criminal behavior and 
imprisonment among individuals with a SIPD and PPD (Dixon et al., 1991; Raja and 
Azzoni, 2005). Future research could also determine whether a forensic history with 
and without a history of ASPD is differentially associated with the presence of a 
SIPD.  
 
This is the first study to determine if a trauma history is differentially associated with 
a SIPD or PPD in first episode patients. The SIPD group were 23 times more likely to 
have a trauma history than the PPD group. However, there was no statistical 
difference in the mean number of traumatic events, and those with PPD experienced 
their first traumatic event at a significantly younger age. Previous research with first 
episode patients reported a significantly higher prevalence of substance use disorders 
among those with a trauma history, which may provide some indication of an 
individual’s coping style (Conus et al., 2010). Similarly, substance use and trauma 
exposure have been shown to significantly increase the risk of psychotic symptoms 
beyond that posed by either risk factor independently (Harley et al., 2010). The later 
age of first trauma in the SIPD group could suggest an increased risk for trauma 
exposure when intoxicated. Both substance use and trauma, regardless of causality, 
may represent significant vulnerability factors that increase the risk for SIPD but 
further exploration is needed. 
 
Participants with SIPD were less likely to have a family history of psychosis. This is 
consistent with growing evidence that substance use increases the risk of psychosis in 
the absence of a family history (van Os et al., 2002; Verdoux et al., 2003). Substance 
use may result in neurochemical alterations, which precipitate the onset of psychosis 
in the absence of genetic vulnerability (Bowers et al., 1995; Brady et al., 1991; Caton 
et al., 2006). Therefore, SIPD and PPD may have different etiological mechanisms. 
Future research needs to examine the influence of substance-induced psychotic 
symptoms, rather than treating individuals with substance use and first episode 
psychosis as a homogeneous group.   
 
4.1 Limitations 
The small sample limits the generalizability of the current findings, but is nonetheless 
sufficient for the analyses conducted (Tabachnick and Fidell, 2007  ). While 
confirmation of self-reported substance use through biological measures would have 
strengthened the study, self-reported substance use provides a more sensitive measure 
of substance use than collateral reports, laboratory tests (blood, urine, hair and saliva) 
and medical examinations among individuals with psychosis (McPhillips et al., 1997; 
Selten et al., 2002; Wolford et al., 1999).  
 
4.2 Clinical implications 
This group of first episode patients reported severe levels of psychopathology, serious 
enough to warrant hospitalization, and the use of high dose antipsychotic medication. 
The high rates of SIPD identified in the current sample, indicate individuals with 
SIPD experience severe and distressing psychotic symptoms that require intensive 
inpatient treatment. Previous research indicates that up to 25% of individuals with a 
SIPD develop a PPD over the subsequent 12 months (Caton et al., 2007). However, 
many individuals with a SIPD either don’t present to mental health services or only 
receive emergency treatment without follow-up (Schanzer et al., 2006). Thus, it is an 
important clinical priority to ensure that this opportunity for early intervention is not 
missed.  
 
Many young people presenting with a SIPD may be misdiagnosed with a PPD. Such a 
diagnosis may result in stigmatization, unnecessary prolonged use of antipsychotic 
medication and adverse effects on social, educational and vocational outcomes. In 
cases of diagnostic uncertainty, clinicians should conduct a thorough assessment over 
time and consider delaying antipsychotic treatment while providing psychosocial and 
symptomatic pharmacological treatment and/or withdrawal management (if required). 
The extent of trauma  exposure in this first episode group also highlights the 
importance of specialist trauma interventions in this population (Lu et al., 2008).  
 
5.0 Conclusions 
Substance-using first episode psychosis inpatients with SIPD can be differentiated by 
the presence of current cannabis dependence, a history of trauma and the absence of a 
family history of psychosis. Together these variables correctly identified 78.7% of 
patients with a SIPD. The early detection, appropriate treatment and follow up of first 
episode patients with SIPD in acute care settings may prevent the development of a 
chronic and debilitating PPD.  
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Table 1  
Comparison of FEP patients with SIPD and PPD on demographic and historical 
variables. 
 
Variable Total 
sample 
(n=61) 
PPD 
(n=27) 
SIPD 
(n=34) 
p-value 
 
Sex, n (%) 
  Male 
 
47 (77.0) 
 
19 (70.4) 
 
28 (82.4) 
 
0.42 
Age, M (SD) 20.6 (2.4) 21.3 (2.5) 20.1 (2.0) 0.08 
Relationship status, n 
(%) 
  Single 
  In relationship 
 
41 (67.2) 
20 (32.8) 
 
19 (70.4) 
8 (29.6) 
 
22 (64.7) 
12 (35.3) 
 
 
0.85 
Education, n (%)  
   Year 12 
 
18 (29.5) 
 
8 (29.6) 
 
10 (29.4) 
 
1.00 
Employment, n (%) 
Employed 
Unemployed 
 
28 (47.5) 
33 (52.5) 
 
14 (52.9) 
13 (47.1) 
 
14 (40.7) 
20 (59.3) 
 
 
0.49 
Homeless, n (%) 15 (26.6) 6 (22.2) 9 (26.5) 0.93 
Living, n (%)   
  Alone 
  With Others  
 
13 (21.3)          
48 (78.9) 
 
7 (25.9)           
20 (74.1) 
 
6 (17.6)           
28 (82.1) 
 
0.64 
Family history, n (%) 
  Psychosis 
  Substance use  
  Mental illness 
 
26 (42.6) 
32 (52.5) 
52 (85.2) 
 
16 (59.3) 
14 (52.9) 
24 (88.9) 
 
10 (29.4) 
18 (51.9) 
28 (82.4) 
 
0.03* 
1.00 
0.73 
Forensic history, n (%) 39 (63.9) 13 (48.1) 26 (76.5) 0.04* 
Trauma  
  Trauma history, n (%) 
  Age first trauma, M 
(SD) 
  Total traumas, M (SD) 
 
52 (85.2) 
9.4 (6.3) 
3.3 (2.3) 
 
19 (70.4) 
6.7 (6.3) 
2.7 (2.5) 
 
33 (97.1) 
11.5 (5.5) 
3.8 (2.1) 
 
0.01* 
0.00** 
0.07 
  Note: T-tests *p<0.05 **p<0.001  
Table 2  
Group comparisons of FEP patients with SIPD and PPD on DSM-IV substance 
dependence. 
 
Variable Total sample 
(n = 61) 
PPD  
(n=27) 
SIPD  
(n=34) 
p-value 
Age onset, M (SD)  
  Alcohol use 
    Weekly use 
  Cannabis use 
    Weekly use 
 
 
 
 
 
13.96 (2.43) 
16.33 (2.67) 
14.41 (2.34) 
15.61 (2.46) 
 
12.74 (3.18) 
15.44 (1.81) 
13.26 (2.81) 
15.85 (3.25) 
 
0.10 
0.76 
0.10 
0.77 
Substance use in past 
month, M (SD)  
  Alcohol: SDU/day 
  Cannabis: grams/day 
  Ecstasy: pills/day 
  Methamph: grams/day 
  Ice: grams/day 
  Days abstinent 
 
 
6.41 (4.31) 
1.37 (1.16) 
1.77 (0.97) 
0.64 (0.28) 
0.86 (0.78) 
15.60 (8.52) 
 
 
6.83 (5.66) 
0.64 (0.72) 
1.5 (0.00) 
0.30 (0.16) 
.54 (0.45) 
21.12 (7.31) 
 
 
6.10 (2.97) 
1.96 (1.13) 
1.83 (1.07) 
0.78 (0.50) 
0.95 (0.85) 
11.38 (6.86) 
 
 
0.58 
0.00** 
0.77 
0.02* 
0.44 
0.00** 
DSM-IV dependence, n 
(%) 
 Alcohol 
 Cannabis 
 Stimulants 
 Heroin 
 Hallucinogens 
 Polysubstance 
 
 
13  (21.3) 
42  (68.9) 
19 (31.1) 
10  (16.4) 
1  (1.6) 
25 (41.0) 
 
 
13 (22.2) 
12(44.4) 
3 (11.1) 
5  (14.7) 
- 
6  (22.2) 
 
 
 
7 (20.6) 
30 (88.2) 
16 (47.1) 
5 (18.5) 
1 (2.9) 
16 (47.1) 
 
 
 
1.00 
0.00** 
0.00** 
0.96 
1.00 
0.02* 
Note: T-tests *p<0.05 **p<0.001; Methamph: methamphetamines 
  
Table 3  
Group comparisons of FEP patients with SIPD and PPD on clinical and functional 
variables.  
 
Variables Total sample 
(n = 61) 
PDD 
(n = 27) 
SIPD 
(n = 34) 
p-value 
 
Medication, M (SD) 
(Haloperidol Equiv. 
mg) 
 
4.52 (3.61) 
 
5.00 (3.86) 
 
4.13 (3.31) 
 
0.36 
DUP†, M (SD) 2.9 (4.4) 3.4 (4.2) 2.4 (4.6) 0.42 
aBPRS, M (SD) 
   Manic excitement 
   Positive 
   Negative 
   Depression/anxiety  
   Total score 
 
16.4 (7.5) 
18.3 (5.6) 
9.4 (3.9) 
12.6 (5.4) 
67.0 (12.8) 
 
15.9 (7.0) 
17.7 (5.4) 
9.3 (3.9) 
12.1 (5.5) 
64.3 (9.7) 
 
16.7 (7.5) 
18.9 (5.8) 
9.5 (4.0) 
13.0 (5.5) 
69.2 (14.6) 
 
0.66 
0.42 
0.84 
0.52 
0.14 
aBPRS (items), M 
(SD) 
   Anxiety 
   Hostility 
   Suicidality 
 
3.8 (1.8) 
4.4 (1.8) 
2.7 (1.8) 
 
3.3 (1.5) 
3.9 (1.7) 
2.9 (1.9) 
 
4.3 (1.8) 
4.8 (1.8) 
2.5 (1.7) 
 
0.02* 
0.05* 
0.48 
Hallucinations, n (%) 
  Auditory  
  Visual  
 
34 (55.7) 
25 (41.0) 
 
16 (59.3) 
12 (44.4) 
 
18 (52.9) 
13 (38.2) 
 
0.81 
0.82 
bInsight, M (SD) 
  Awareness 
    Mental disorder 
    Needs for meds 
    Social consequence 
  Unawareness 
    Hallucinations 
    Delusions 
    Thought disorder 
  Misattribution 
    Hallucinations 
    Delusions 
    Thought disorder 
 
 
2.5 (1.7) 
2.6 (1.5) 
2.6 (1.6) 
 
2.6 (1.6) 
3.2 (1.6) 
3.7 (1.5) 
 
2.3 (1.6) 
2.1 (1.4) 
2.3 (1.4) 
 
 
3.1 (1.8) 
2.9 (1.6) 
3.1 (1.8) 
 
3.3 (1.5) 
3.6 (1.6) 
4.3 (1.4) 
 
2.6 (1.7) 
1.5 (0.9) 
2.5 (1.9) 
 
 
2.0 (1.4) 
2.3 (1.4) 
1.9 (1.4) 
 
2.2 (1.4) 
3.0 (1.5) 
3.3 (1.5) 
 
2.1 (1.6) 
2.4 (1.5) 
2.3 (1.3) 
 
 
0.01* 
0.10 
0.05 * 
 
0.04 * 
0.13 
0.07 
 
0.56 
0.05* 
0.78 
Functioning, M (SD) 
  cGAF  
  dSOFAS 
 
37.6 (7.6) 
44.2 (9.0) 
 
36.3 (6.91) 
41.8 (8.9) 
 
38.6 (8.0) 
46.1 (8.6) 
 
0.25 
0.06 
ePAS, M (SD) 
  Adolescent 
  Adult   
  General 
 
0.39 (0.15) 
0.38 (0.17) 
0.42 (0.16) 
 
0.37 (0.13) 
0.39 (0.18) 
0.42 (0.16) 
 
0.40 (0.17) 
0.33 (0.17) 
0.43 (0.16) 
 
0.40 
0.22 
0.80 
Note.  aBrief Psychiatric Rating Scale; bThe Scale to Assess Unawareness of Symptoms; cGlobal Assessment of Functioning; 
dSocial and Occupational Functioning Assessment Scale; ePremorbid Adjustment Scale; †Duration of Untreated Psychosis - 
original values reported as no difference in the results for transformed/untransformed variables found; *p<0.05 
 
 
 Table 4 
Logistic regression analyses predicting a diagnosis of SIPD.  
 
Variables B S.E Wald df p Odds 
Ratio 
95% CI 
Historical  
  Trauma hx    
  Family hx psych 
  Forensic hx 
 
2.43 
-1.27 
1.17 
 
1.13 
0.61 
0.62 
 
4.60 
4.41 
3.52 
 
1 
1 
1 
 
0.03* 
0.04* 
0.06 
 
11.35 
0.28 
3.21 
 
1.23-104.56 
0.09-0.92 
0.95-10.89 
Clinical  
 aBPRS hostility 
  Insight 
  Cannabis Dep 
 
0.35 
-0.32 
2.36 
 
0.17 
0.20 
0.72 
 
3.96 
2.65 
10.67 
 
1 
1 
1 
 
0.05 
0.10 
0.01* 
 
1.41 
0.72 
10.60 
 
1.00-1.99 
0.49-1.07 
2.57-43.67 
Final model 
  Trauma hx 
  Family hx psych   
  Cannabis dep 
 
3.14 
-1.70 
2.97 
 
1.26 
0.74 
0.80 
 
6.25 
5.31 
11.25 
 
1 
1 
1 
 
0.01* 
0.02* 
0.001** 
 
23.20 
0.18 
14.83 
 
1.97-272.58 
0.04-0.78 
3.07-71.71 
Note: *p<0.05, **p<0.001; aBPRS: Brief Psychiatric Rating Scale; Hx - history; psych - psychosis; dep - dependence; Dependant 
variable: SIPD diagnosis (vs. PPD) ; Historical model: entered trauma history, forensic history and family history of psychosis as 
independent variables; Clinical model entered BPRS hostility, hostility, cannabis dependence (current) and insight into having a 
mental disorder as independent variables; Final model entering family history of psychosis, forensic history and cannabis 
dependence (current) as independent variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
